Immune Control Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Immune Control General Information
Description
Developer of serotonin-based immunotherapeutics intended to treat the causative elements of autoimmunity with a more favorable side effect profile than traditional treatments. The company offers orally available, small molecules that modulate the immune system through serotonin receptors on immune cells by blocking certain serotonin receptors on activated immune cells, thereby enabling healthcare professionals to kill activated immune cells selectively and treat autoimmune/inflammatory diseases, hematologic cancers and organ transplant rejection.
Contact Information
Website
www.immunecontrol.comCorporate Office
- 200 Barr Harbor Drive
- Four Tower Bridge, Suite 400
- Conshohocken, PA 19428
- United States
Corporate Office
- 200 Barr Harbor Drive
- Four Tower Bridge, Suite 400
- Conshohocken, PA 19428
- United States
Immune Control Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 17-Jun-2010 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A1) | 01-Apr-2008 | Completed | Startup | |||
| 1. Early Stage VC (Series A) | 01-Jun-2005 | $11.3M | $11.3M | Completed | Product Development |
Immune Control Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A |
Immune Control Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Anthem Capital Management | Venture Capital | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| NewSpring Capital | Growth/Expansion | Minority | ||
| Quaker Partners | Venture Capital | Minority |
Immune Control FAQs
-
When was Immune Control founded?
Immune Control was founded in 2001.
-
Where is Immune Control headquartered?
Immune Control is headquartered in Conshohocken, PA.
-
What industry is Immune Control in?
Immune Control’s primary industry is Drug Discovery.
-
Is Immune Control a private or public company?
Immune Control is a Private company.
-
What is Immune Control’s current revenue?
The current revenue for Immune Control is .
-
How much funding has Immune Control raised over time?
Immune Control has raised $17.3M.
-
Who are Immune Control’s investors?
Anthem Capital Management, Domain Associates, NewSpring Capital, and Quaker Partners have invested in Immune Control.
-
When was Immune Control acquired?
Immune Control was acquired on 17-Jun-2010.
-
Who acquired Immune Control?
Immune Control was acquired by Corridor Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
